IGC Pharma comments on potential reclassification of cannabis

The company said, “Recent reports indicating a possible shift in federal scheduling have coincided with renewed market interest across the cannabinoid landscape, reflecting expectations that a clearer federal posture may reduce long-standing friction around research, manufacturing, and financial infrastructure. While such developments would not legalize cannabis or eliminate regulatory oversight, they underscore a broader transition toward recognizing clinically validated cannabinoid medicines as part of the mainstream pharmaceutical ecosystem. IGC Pharma (IGC) believes it occupies a distinct position at this inflection point: Unlike consumer-facing cannabis or hemp companies, IGC operates within the FDA-regulated drug-development pathway, with a focused strategy centered on neurological disorders and low-dose cannabinoid formulations designed for therapeutic effect with minimal psychoactivity. The Company’s lead candidate, IGC-AD1, is currently being evaluated in a Phase 2 clinical trial for agitation associated with Alzheimer’s disease.” “We built IGC Pharma for this moment,” said Ram Mukunda, CEO. “As federal policy evolves, the market is beginning to distinguish between unregulated cannabinoid exposure and true pharmaceutical development. We believe IGC stands alone as a publicly traded company focused on FDA-driven, clinically tested cannabinoid therapeutics for Alzheimer’s disease, one of the largest and most urgent unmet needs in medicine.”